Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 14, 2022; 28(38): 5626-5635
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5626
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5626
Group | n | 5-year survival rate | Log rank test | |
All patients | P = 0.676 | |||
Adjuvant chemotherapy | 63 | 96% | ||
Postoperative observation | 262 | 90% | ||
Risk score | P < 0.001 | |||
Score 0 group | 98 | 92% | ||
Score 1 group | 152 | 95% | ||
Score 2 group | 69 | 80% | ||
Score 3 group | 6 | 50% | ||
Score 0 group | P = 0.825 | |||
Adjuvant chemotherapy | 13 | 92% | ||
Postoperative observation | 85 | 92% | ||
Score 1 group | P = 0.308 | |||
Adjuvant chemotherapy | 22 | 92% | ||
Postoperative observation | 130 | 96% | ||
Score 2-3 group | P = 0.021 | |||
Adjuvant chemotherapy | 28 | 95% | ||
Postoperative observation | 47 | 61% |
- Citation: Xu Q, Kang WZ, Xiong JP, Shao XX, Li WK, Hu HT, Tian YT. A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy. World J Gastroenterol 2022; 28(38): 5626-5635
- URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5626.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5626